ZJ43

ZJ43 is a potent NAAG peptidase inhibitor, with an IC50 of 2.4 nM and a Ki of 0.8 nM. ZJ43 sufficiently activates group II mGluR and reduces some of the behavioral effects of PCP. ZJ43 shows an analgesic effect in neuropathic and inflammatory and pain models[1].

Product Specifications

CAS Number

[723331-20-2]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Aminopeptidase; mGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zj43.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H](C(O)=O)CCC(O)=O)N[C@H](C(O)=O)CC(C)C

Molecular Formula

C12H20N2O7

Molecular Weight

304.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Olszewski RT, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004 May;89 (4) :876-85.|[2]Yamamoto T, et al. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci. 2004 Jul;20 (2) :483-94.